How NGM Bio Intends To Build An Old-School Biotech

NGM Biopharmaceuticals CEO Jeff Jonker discusses the company's lead program in NASH and its other R&D activities and business strategy in an interview with Scrip's Mike Ward.

Video interview
NGM Bio's Jeff Jonker talks NASH

With the hepatitis C challenge broadly solved, the leading cause of expensive liver transplants is now a disease called non-alcoholic steatohepatitis (NASH), which, not surprisingly, is attracting a lot of attention from companies looking to develop treatments.

Jeff Jonker, president of NGM Biopharmaceuticals Inc., a San Francisco-based biotech, explains to Scrip how he is positioning its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category